NewsRx

Search our medical news database

Obesity

Phase Ic dose-sequencing study using PYY3-36 obesity drug nasal spray begins

Published in Women's Health Weekly, March 25th, 2004

Nastech Pharmaceutical Co., Inc., (NSTK) announced the initiation of a phase Ic in-clinic, parallel, multiple-dose, randomized, double-blind, placebo-controlled, dose-sequencing study using its proprietary investigational PYY3-36 Nasal Spray for obesity.

The study involves 36 normal, healthy male and female subjects between 18-65 years of age with a Body Mass Index of 30-40 kg/m2 who will be randomized to treatment groups, each of which will receive three daily administrations of various dose sequences of PYY or placebo over 8 consecutive days. The study is being conducted primarily to determine how many times a day PYY will need to be administered to achieve...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook